Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Conditions:   Melanoma;   Renal Cell Carcinoma;   NSCLC;   Hepatocellular Carcinoma;   Urothelial Cancer;   Gastric Adenocarcinoma;   HNSCC;   Esophageal Adenocarcinoma;   Microsatellite Instability-High Solid Malignant Tumor Interventions:   Drug: Nivolumab or Pembrolizumab (dependent upon approved indication);   Drug: Metformin;   Drug: Rosiglitazone Sponsor:   Dan Zandberg Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials